Abstract 414P
Background
Gastrointestinal stromal tumours (GIST) are the most common mesenchymal tumours originating from the interstitial cells of Cajal and differentiates from other mesenchymal neoplasm by expression of CD117 oncogene. Most GISTs are found in the stomach followed by small bowels. Using NIH risk groups, the low risk GISTs were less frequent and the highest risk group was the commonest one. The main aim of this study was to evaluate demographic data , assess risk groups and study the clinical outcomes among GIST patients attending the Medical Oncology department , Yangon General hospital from 2015 to 2017.
Methods
Retrospective descriptive study.
Results
Among 73 patients, male: female is 2:1. The most common age group was 51-60 years. Regarding tumor site, small intestine was the most common site and the most patients were found to have tumor size between 11 to 20cm. According to TNM staging, 48% of patients were stage III. By using NIH risk stratification, it was found that 84% of patients were in high risk group. Tumour resection was performed in 77.8% and palliative resection was done in 22.2% of patients. CD117 immunostaining was performed in all 73 patients but CD117 expression was found in 69 patients. 4 patients were CD117 negative but CD34 positive. Therapy with imatinib (400–600mg) was given in 73 patients. Among them, 13 patients was occurred loss follow-up and could not assessed due to social and transportation difficulties. Three patients were expired due to disease progression. 57 patients were alive and taken imatinib up to 3 year. We initially assessed with USG and if there was suspected lesion in USG, we did further advanced imaging like CT. Among these patients who took imatinib up to 3 years, 5 patients was found to have recurrence and change to second line therapy. 52 out of 73 patients remained clinically stable and no recurrence up to 3 years. The most common side effect was generalized edema. The other side effects were whitening of skin and rash . 2 patients suffered dyspnea on exertion and assessed with echocardiogram showing reduced ejection fraction. Dose adjustment was done to these patients. 1 patient was found to have liver function derangement.Table:
414P
Tumour Profile | ||
---|---|---|
Tumour site distribution | No | Percentange |
small intestine | 37 | 51 |
Stomach | 17 | 23 |
Colon and rectum | 10 | 14 |
Extra Gastrointestinal Tract | 9 | 12 |
Tumour sizes distribution | ||
< 10 cm | 24 | 33 |
10-20 cm | 41 | 56 |
>20 cm | 8 | 11 |
Tumour stages distribution | ||
Stage I | 9 | 12 |
Stage II | 13 | 18 |
Stage III | 35 | 48 |
Stage IV | 16 | 22 |
NIH risk distribution | ||
Low | 6 | 8 |
Intermediate | 6 | 8 |
High | 61 | 84 |
Conclusions
This study showed most patients presented with larger tumour sizes, high NIH risk and small intestine. Those who received imatinib up to 3 years had low rate of recurrence and well tolerated.
Clinical trial identification
Editorial acknowledgement
It would not have been possible without the guidance of our professors and co-authors who contributed their valuable expertise to the concepts displayed in this abstract.
Legal entity responsible for the study
Medical Oncology, Yangon General Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
220P - An outcome analysis of robotassisted radical nephroureterectomy with extended template lymphadenectomy for upper tract urothelial carcinoma
Presenter: Ashwin Tamhankar
Session: Poster display session
Resources:
Abstract
221P - Comparative analysis of first-line immune checkpoint inhibitor versus carboplatin-based chemotherapy for cisplatin-ineligible metastatic urothelial carcinoma: A multicenter, retrospective real-world evidence
Presenter: Hsiang‐Lan Lai
Session: Poster display session
Resources:
Abstract
222P - Does tumor grade really improve the prognostic ability of the staging system for men with penile cancer: A SEER database analysis
Presenter: Ravi Kanodia
Session: Poster display session
Resources:
Abstract
223TiP - EV-301: A phase III trial in progress evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma
Presenter: Daniel Petrylak
Session: Poster display session
Resources:
Abstract
230P - Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort
Presenter: Lingying Wu
Session: Poster display session
Resources:
Abstract
231P - Cost-effectiveness of olaparib vs routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore
Presenter: David SP Tan
Session: Poster display session
Resources:
Abstract
233P - Incorporation of correlative studies in ovarian cancers in the era of precision medicine: Assessment of accountability and utility
Presenter: Nadia Hitchen
Session: Poster display session
Resources:
Abstract
234P - Implementation of mainstream BRCA testing in epithelial ovarian cancer in a tertiary centre
Presenter: Edbert Wong
Session: Poster display session
Resources:
Abstract
235P - The efficacy of radiation therapy in ovarian carcinoma: A propensity score analysis of a population-based study
Presenter: Jian-Guo Zhou
Session: Poster display session
Resources:
Abstract
236P - Front-line maintenance therapy for platinum-sensitive ovarian cancer: What’s next PARP inhibitors?
Presenter: Han Gong
Session: Poster display session
Resources:
Abstract